The use of vital and morbidity statistics for the detection of adverse drug reactions and for monitoring of drug safety.
D000230:Adenocarcinoma / Q000139:chemically induced; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000139:chemically induced; D001650:Bile Duct Neoplasms / Q000139:chemically induced; D002648:Child; D003276:Contraceptives, Oral / Q000009:adverse effects; D004054:Diethylstilbestrol / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D004480:Ectromelia / Q000139:chemically induced; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006801:Humans; D006912:Hydroxyquinolines / Q000009:adverse effects; D008750:Methyldopa / Q000009:adverse effects; D009017:Morbidity; D009187:Myelitis / Q000139:chemically induced; D009203:Myocardial Infarction / Q000139:chemically induced; D009902:Optic Neuritis / Q000139:chemically induced; D011655:Pulmonary Embolism / Q000139:chemically induced; D013549:Sweetening Agents / Q000009:adverse effects; D013566:Sympathomimetics / Q000009:adverse effects; D013577:Syndrome; D013792:Thalidomide / Q000009:adverse effects; D014594:Uterine Neoplasms / Q000139:chemically induced; D014625:Vaginal Neoplasms / Q000139:chemically induced; D014798:Vital Statistics
D003276:Contraceptives, Oral; D004967:Estrogens; D006912:Hydroxyquinolines; D013549:Sweetening Agents; D013566:Sympathomimetics; D013792:Thalidomide; D008750:Methyldopa; D004054:Diethylstilbestrol